TYRAClinical Trials•prnewswire•August 21, 2025 at 12:00 PM

Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia

Sentiment:Positive (70)

Summary

-Dabogratinib is the only oral FGFR3-selective inhibitor in clinical development for achondroplasia- -Initial results from safety sentinel cohort expected in 2H 2026- CARLSBAD, Calif., Aug. 21, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology...

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on August 21, 2025 by prnewswire